0,1,2,3,4
Table 6.5.2: Randomised phase III controlled trials - first-line treatment of mCRPC,,,,
Study  Intervention  Comparison  Selection criteria  Main outcomes,,,,
DOCETAXEL,,,,
SWOG 99-16   2004 [1200],"docetaxel/EMP,   every 3 weeks,   60 mg/m2, EMP   3 x 280 mg/day","mitoxantrone,   every 3 weeks,   12 mg/m2   prednisone 5 mg   BID",,"OS: 17.52 vs. 15.6 mo.   (p = 0.02, HR: 0.80;   95% CI: 0.67-0.97)   PFS: 6.3 vs. 3.2 mo.   (p < 0.001)"
"TAX 327   2004, 2008   [1190,1201]","docetaxel, every   3 weeks, 75 mg/m2   prednisone 5 mg   BID   or   docetaxel, weekly,   30 mg/m2   prednisone 5 mg   BID","mitoxantrone,   every 3 weeks,   12 mg/m2,   Prednisone 5 mg   BID",,"OS: 19.2 for 3 weekly   vs. 17.8 mo. 4-weekly   and 16.3 in the control   group.   (p = 0.004, HR: 0.79,   95% CI: 0.67-0.93)"
ABIRATERONE,,,,
"COU-AA-302   2013, 2014, 2015   [1182, 1183, 1202]",abiraterone +   prednisone,placebo +   prednisone,- No previous docetaxel.   - ECOG 0-1.   -  PSA or radiographic   progression.   - No or mild symptoms.   - No visceral metastases.,"OS: 34.7 vs. 30.3 mo.   (HR: 0.81, p = 0.0033).   FU: 49.2 mo. rPFS:   16.5 vs. 8.3 mo.   (p < 0.0001)"
ENZALUTAMIDE,,,,
PREVAIL   2014 [1185],enzalutamide,placebo,- No previous docetaxel.   - ECOG 0-1.   -  PSA or radiographic   progression.   - No or mild symptoms.   - 10% had visceral mets.,"OS: 32.4 vs. 30.2 mo.   (p < 0.001). FU: 22 mo.   (p < 0.001 HR: 0.71,   95% CI: 0.60-0.84)   rPFS: 20.0 mo. vs.   5.4 mo. HR: 0.186   (95% CI: 0.15-0.23)   p < 0.0001)"
SIPULEUCEL-T,,,,
IMPACT2010   [1196],sipuleucel-T,placebo,-  Some with previous   docetaxel.   - ECOG 0-1.   -  Asymptomatic or   minimally symptomatic.,"OS: 25.8 vs. 21.7 mo.   (p = 0.03 HR: 0.78,   95% CI: 0.61-0.98).    FU: 34.1 mo. PFS:   3.7 vs. 3.6 mo. (no   difference)"
2006 [1203],sipuleucel-T,placebo,- ECOG 0-1.   - No visceral met.   -  No corticosteroids.,OS: 25.9 vs. 21.4 mo.   (p = 0.1). FU: 36 mo.   PFS: 11.7 vs. 10.0 wk.
IPATASERTIB,,,,
IPAtential150  2021 [1197],ipatasertib   (400 mg/d) +   abiraterone   (1000 mg/d) +   prednisone    (5 mg bid),abiraterone +   prednisolone +   placebo,"Previously untreated for   mCRPC, asymptomatic/  mildly symptomatic, with   and without PTEN loss   by IHC","rPFS in PTEN loss   (IHC) population:    18.5 vs. 16.5 mo.    (p = 0.0335, HR: 0.77   95% CI: 0.61-0.98)"
PROpel [1198],olaparib    (300mg BID) +    abiraterone   (1000 mg/d) +   prednisone    (5 mg BID),placebo +   abiraterone +   prednisone,- ECOG 0-1.  -  regardless of HRRm   (retrospective testing).  -  prior taxane for   mHSPC allowed.,HR: 0.66; 95%   CI: 0.54â€“0.81;  (p = 0.001)
